Risk of lymphoma in patients with inflammatory bowel disease

Gastroenterology and Hepatology

Volumn 8, Issue 1, 2012, Pages 45-47

  Lewis, James D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; METHOTREXATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER INCIDENCE; CANCER RISK; CROHN DISEASE; DISEASE ASSOCIATION; ENTERITIS; EPSTEIN BARR VIRUS; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; NOTE; POPULATION; RISK FACTOR;

EID: 84863417670     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (5)

1. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125. (Pubitemid 41025906)
2. Bewtra M, Lewis JD. Safety profile of IBD: lymphoma risks. Gastroenterol Clin North Am. 2009;38:669-689.
3. Beaugerie L, Brousse N, Bouvier AM, et al CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617-1625.
4. Herrinton LJ, Liu L, Weng X, Lewis JD, Hutfless S, Allison JE. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146-2153.
5. Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011;106:1594-1602; quiz 1593, 1603.